Table 1

Measures for individual participant data pairwise meta-analysis

Outcomes
For all infants
Primary outcomeDeath prior to hospital discharge
For infants born before 32 weeks’ gestation
Key secondary outcomes
  • Death (at any time during follow-up)

  • Severe intraventricular haemorrhage on cranial ultrasound (grade 3–4)

  • All grades of intraventricular haemorrhage on cranial ultrasound

  • Necrotising enterocolitis ≥grade 2 (or trialist definition)

  • Late-onset sepsis (where possible defined as clinical sepsis >72 hours after birth)

  • Patent ductus arteriosus requiring treatment (medical and/or surgical)

  • Chronic lung disease (at 36 weeks’ postmenstrual age or trialist defined)

  • Blood transfusion (yes/no)

Other secondary outcomes
  • Death (within 7 days)

  • Other forms of white matter brain injury (eg, periventricular leukomalacia, porencephaly)

  • Respiratory support (mechanical ventilation, CPAP, low nasal flow oxygen)

  • Duration of respiratory support

  • Supplemental oxygen at 36 weeks

  • Retinopathy of prematurity requiring treatment (medical and/or surgical)

  • Drug treatment for hypotension (yes/no)

  • Blood transfusion (number, volume)

  • Hypothermia on admission to neonatal unit

  • Haemoglobin

  • Haematocrit

  • Polycythaemia

  • Jaundice requiring treatment

  • Birth weight

  • Length of stay in NICU/SCU

  • Length of stay in hospital

  • Apgar scores at 1 min and 5 min

  • Long-term developmental disability (assessed using the Bayley III, and/or other tools):

    • Cerebral palsy

    • Neurodevelopmental disability

    • Score on cognitive scale

    • Score on language scale

    • Score on social/emotional scale

    • Score on motor scale

    • Score on behaviour scale

    • Deafness

    • Blindness

For infants born at or after 32 weeks’ gestation
Key secondary outcomes
  • Death at any time (during follow-up)

  • Admission to NICU

  • Blood transfusion (any, number, volume)

Other secondary outcomes
  • Death (within 7 days)

  • Haemoglobin

  • Haematocrit

  • Jaundice requiring treatment

  • Length of stay in NICU/SCU

  • Length of stay in hospital

  • Duration of respiratory support (mechanical ventilation, CPAP, low flow nasal oxygen)

  • Chronic lung disease

  • Late-onset sepsis (>72 hours after birth)

  • Patent ductus arteriosus requiring treatment (medical and/or surgical)

  • Drug treatment for hypotension

  • Hypothermia on admission to neonatal unit or postnatal ward

  • Apgar score at 1 min and 5 min

  • Long-term developmental disability (assessed using the Bayley III, and/or other tools):

    • Cerebral palsy

    • Neurodevelopmental disability

    • Score on cognitive scale

    • Score on language scale

    • Score on social/emotional scale

    • Score on motor scale

    • Score on behaviour scale

    • Deafness

    • Blindness

For all women
Secondary outcomes
  • Maternal death

  • Postpartum haemorrhage

  • Postpartum sepsis requiring treatment

  • Manual removal of placenta

  • Retained placenta

  • Not breastfeeding when baby discharged from hospital

  • Postnatal depression

  • Blood transfusion

Covariates/subgroups
Participant-level characteristics
  • Gestation at birth

  • Type of pregnancy: singleton; multiple

  • Maternal age

  • Mode of birth: caesarean before onset of labour; caesarean after onset of labour; vaginal

  • Onset of labour: spontaneous onset or spontaneous prelabour ruptured membranes; not spontaneous onset or spontaneous prelabour ruptured membranes; not known whether spontaneous onset of labour or spontaneous prelabour ruptured membranes

  • Type of breathing onset: spontaneous breathing onset; supported lung aeration (ventilation); unknown

  • Time of breathing onset relative to cord clamping: before cord clamping/milking; after cord clamping/milking; unknown

  • Sex (male, female, uncertain/other)

  • Ethnicity (trialist defined)

  • Small for gestational age (trialist defined): yes/no

  • Maternal antenatal/intrapartum/postpartum sepsis requiring treatment (trialist defined): yes/no

  • Assessed as needing resuscitation and/or stabilisation (yes/no)

  • Type of uterotonic drug (if any)

Hospital/trial-level characteristics
  • Highest level of neonatal unit available at site: NICU, neonatal unit (some capacity to provide ventilation), special care baby unit (no ventilation available), no neonatal unit or special care baby unit

  • Planned timing of uterotonic drug: before cord clamping; after/at cord clamping; timing mixed or not known

  • Planned position of the baby relative to the placenta while cord intact: level with placenta (between level of woman’s bed and her abdomen/anterior thigh); more than 20 cm below level of placenta; position mixed or not known

  • Need for immediate resuscitation at birth: infants requiring immediate resuscitation at birth excluded; infants requiring immediate resuscitation at birth included; unclear whether infants requiring immediate resuscitation at birth included or excluded

  • Type of consent: waiver of consent; deferred consent; informed consent or assent; type of consent unclear

  • Study year

  • CPAP, continuous positive airway pressure; NICU, neonatal intensive care unit; SCU, special care unit.